Skip to main content

Table 1 Characteristics of patients receiving DrotAA compared with control patients

From: Drotrecogin alfa (activated): real-life use and outcomes for the UK

Characteristic All admissions receiving DrotAA (n = 1,292) Admissions with severe sepsis and ≥2 organ systems failing receiving DrotAA (N = 1,079) Admissions with severe sepsis and ≥2 organ systems failing not receiving DrotAA (n = 15,939)
Age (years; mean ± SD) 58.8 ± 16.0 59.1 ± 16.1 63.3 ± 17.2
Sex (n [%])
   Female 638 (49.4) 535 (49.6) 7,333 (46.0)
   Male 654 (50.6) 544 (50.4) 8,604 (54.0)
Mechanical ventilation on admission or during first 24 hours of stay in critical care (n [%]) 1,163 (90.0) 998 (92.5) 12,060 (75.7)
APACHE II score (mean ± SD)
   Acute physiology score 18.2 (6.5) 18.8 (6.4) 16.0 (6.5)
   Score 21.9 (6.9) 22.6 (6.7) 20.7 (7.2)
ICNARC model physiology score (mean ± SD) 29.1 (9.0) 30.4 (8.4) 24.9 (9.4)
Serious conditions in past medical historya (n [%])
   Liver 10 (0.8) 9 (0.8) 384 (2.4)
   Cardiovascular 5 (0.4) 5 (0.5) 263 (1.7)
   Respiratory 23 (1.8) 23 (2.1) 630 (4.0)
   Renal 14 (1.1) 12 (1.1) 315 (2.0)
   Immunosuppressed 92 (7.1) 78 (7.2) 1,545 (9.7)
Admission typeb (n [%])
   Medical 939 (72.7) 789 (73.1) 11,375 (71.4)
   Elective surgical 56 (4.3) 32 (3.0) 819 (5.1)
   Emergency surgical 297 (23.0) 258 (23.9) 3,745 (23.5)
Organ systems failing during first 24 hours of stay in critical care (n [%])
   Cardiovascular 1,235 (95.6) 1,070 (99.2) 15,136 (95.0)
   Respiratory 1,166 (90.3) 1,005 (93.1) 13,722 (86.1)
   Renal 480 (37.7) 427 (40.0) 4,274 (27.1)
   Haematological 229 (17.7) 199 (18.4) 2,290 (14.4)
   Metabolic acidosis 990 (76.6) 872 (80.8) 9,674 (60.7)
Number of organ systems failing during first 24 hours of stay in critical care (n [%])
   <2 60 (4.7) N/A N/A
   2 238 (18.4) 198 (18.4) 6,809 (42.7)
   3 498 (38.5) 433 (40.1) 5,664 (35.5)
   4 398 (30.8) 362 (33.6) 2,844 (17.8)
   5 98 (7.6) 86 (8.0) 622 (3.9)
Primary site of infectionc (n [%])
   Lung 495 (41.9) 423 (42.8) N/R
   Abdomen 478 (40.4) 390 (39.5) N/R
   Urinary tract 57 (4.8) 51 (5.2) N/R
   Other 158 (13.4) 131 (13.3) N/R
Positive blood cultured (n [%]) 438 (40.3) 381 (42.1) N/R
Organisms cultured (n [%])
   Any 814 (64.6) 692 (65.8) N/R
   Gram-negative 399 (49.0) 331 (47.8) N/R
   Gram-positive 437 (53.7) 382 (55.2) N/R
   Fungus 101 (12.4) 81 (11.7) N/R
Deaths within 96 hours of unit admission (n [%]) 166 (12.9) 151 (14.0) 3,315 (20.8)
Mortality (deaths [%])
   Unit 449 (34.8) 385 (35.7) 5,404 (33.9)
   Hospitale 567 (45.0) 484 (45.4) 7,438 (46.7)
Location at 28-days (n [%])
   Died 463 (35.8) 398 (36.9) 6,541 (41.0)
   Unit 240 (18.6) 177 (16.4) 888 (5.6)
   Hospital 363 (28.1) 312 (28.9) 3,865 (24.3)
   Out of Hospitale 226 (17.5) 192 (17.8) 4,645 (29.1)
Unit length of stay (days; median [IQR])
   Unit survivors 14.2 (8.1–24.9) 13.8 (8.0–23.2) 5.0 (2.2–11.0)
   Unit nonsurvivors 7.2 (2.3–16.3) 6.4 (2.0–15.6) 2.5 (1.0–7.4)
Hospital length of stay (days; median [IQR])f
   Hospital survivors 44 (25–69) 44 (24–66) 29 (16–52)
   Hospital nonsurvivors 15 (6–31) 14 (5–28) 11 (4–25)
Destination following discharge from hospital housing critical care unit (n [%])
Another acute hospital 41 (6.5) 29 (5.5) 537 (6.8)
   Hospice or equivalent 8 (1.3) 8 (1.5) 40 (0.5)
   Long-term institutional care 13 (2.0) 12 (2.3) 126 (1.6)
   Rehabilitation unit 43 (6.8) 35 (6.6) 549 (7.0)
   Normal residence 531 (83.5) 446 (84.2) 6,652 (84.2)
  1. aFourteen (1.1%) admissions had no evidence to assess past medical history. Evidence defined as follows, during prior 6 months (except those terms highlighted with asterisk, which are not restricted to the preceding 6 months): liver (biopsy proven cirrhosis, portal hypertension, hepatic encephalopathy); cardiovascular (very severe cardiovascular disease [New York Heart Association functional classification IV]); respiratory (severe respiratory disease [shortness of breath with light activity, for example walking 20 m on level ground], home ventilation); renal (chronic renal replacement therapy for irreversible renal disease); immunosuppressed (AIDS*, steroid treatment [daily], radiotherapy, chemotherapy, metastatic disease, acute myelogenous/lymphocytic leukaemia or multiple myeloma, chronic myelogenous/lymphocytic leukaemia, lymphoma, congenital immunohumoral or cellular immune deficiency state*). bSurgical admissions are defined as those admitted directly to the unit from theatre and recovery. cPrimary site of infection was not reported for 110 (8.5%) admissions. dA blood culture was reported as not done for 181 (14.0%) admissions. eDischarged alive from acute hospital at or before 28 days. fExcluding readmissions within the same hospital stay. APACHE, Acute Physiology and Chronic Health Evaluation; DrotAA, Drotrecogin alfa (activated); ICNARC, Intensive Care National Audit & Research Centre; IQR, interquartile range; SD, standard deviation.